Cell-Del®巨噬细胞清除脂质体套装

本便捷组合套装内含1 瓶氯膦酸盐脂质体( Clodronate Liposomes)与1 瓶等体积空白对照脂质体(Control Liposomes)。当实验动物或细胞接触氯膦酸盐脂质体后，吞噬细胞会通过吞噬作用摄取组织局部或血清中的脂质体；随后脂质体在细胞质内释放氯膦酸盐，最终导致细胞凋亡。游离态氯膦酸盐无法穿透细胞膜，因此不会引发细胞死亡。

脂质体(Liposomes)是一种人工膜，由磷脂和胆固醇构成。一般直径在25nm-1um之间。细胞体外(invitro)吞噬实验显示，随着脂质体(Liposome)的直径从100nm到1um，细胞吞噬的脂质体(Liposomes)随之增多，直至高达2um；动物体内(invivo)实验显示，随着直径增大，体内吞噬的脂质体(Liposomes)更多。脂质体(Liposomes)和巨噬细胞（Macrophages）间有最小的间隙，辅以改变脂质体(Liposomes)表面的电荷，尤其是负电荷，能更好促进巨噬细胞对脂质体的吞噬。采用多室的脂质体结构，让包裹更多的药物，从而到达效应的阈浓度。

本品支持多种给药方式，包括静脉注射、腹腔注射、皮下注射、鼻内给药、气管内给药等。对实验动物单次静脉注射 0.2 mL，24 小时后即可实现肝脏F4/80和CD11b双阳巨噬细胞90%以上；脾脏中 80%~90%红髓巨噬细胞的清除效果。针对体重 20~25 克的实验动物，为保证稳定的巨噬细胞清除效果，建议初始给药剂量为 0.15~0.2 mL（静脉或腹腔注射均可）；结合具体实验场景，可酌情优化使用剂量。

套装组成：每套标准氯膦酸盐脂质体套装包含 1 瓶氯膦酸盐脂质体、1 瓶对照脂质体

脂质组分：磷脂酰胆碱、胆固醇

平均粒径：0.5~3.5 微米

包封药物：二氯膦酸钠（CAS 号：22560-50-5），浓度 5 mg/mL

缓冲体系：磷酸盐缓冲液

pH 值：7.0~7.5

保质期：未开启瓶体，置于 2~8 ℃环境下，有效期 6 个月

储存条件：4 ℃避光保存，严禁冷冻

运输方式：使用保温包装+蓝冰运输

注意事项

• 产品禁止冻存，避免低于0 ℃。

• 产品静置于冰箱中会出现分层现象（瓶底产生沉淀，上层为澄清液）。

• 使用前请轻柔摇晃，直至体系混合均匀，操作过程中避免产生气泡。

• 产品禁止分装。

• 产品避免接触破环脂质体结构的有机试剂和离子去垢剂。

0. Xia Y, Xie Y, Yu Z, Xiao H, Jiang G, Zhou X, Yang Y, Li X, Zhao M, Li L, Zheng M, Han S, Zong Z, Meng X, Deng H, Ye H, Fa Y, Wu H, Oldfield E, Hu X, Liu W, Shi Y, Zhang Y. The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant Discovery. Cell. 2018 Nov 1;175(4):1059-1073.e21. doi: 10.1016/j.cell.2018.08.070. Epub 2018 Sep 27. PMID: 30270039.  PubMed  (2018年，产品首次被Cell引用)

1. van Rooijen N, van Nieuwmegen R. Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate. An enzyme-histochemical study. Cell Tissue Res. 1984;238(2):355-8. doi: 10.1007/BF00217308. PMID: 6239690.  PubMed 

2. van Rooijen N, van Nieuwmegen R, Kamperdijk EW. Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate. Ultrastructural aspects of elimination of marginal zone macrophages. Virchows Arch B Cell Pathol Incl Mol Pathol. 1985;49(4):375-83. doi: 10.1007/BF02912114. PMID: 2867636. PubMed 

3. Claassen E, Kors N, van Rooijen N. Immunomodulation with liposomes: the immune response elicited by liposomes with entrapped dichloromethylene-diphosphonate and surface-associated antigen or hapten. Immunology. 1987 Apr;60(4):509-15. PMID: 2953668; PMCID: PMC1453280. PubMed 

4. van Rooijen N, Kors N, ter Hart H, Claassen E. In vitro and in vivo elimination of macrophage tumor cells using liposome-encapsulated dichloromethylene diphosphonate. Virchows Arch B Cell Pathol Incl Mol Pathol. 1988;54(4):241-5. doi: 10.1007/BF02899217. PMID: 2895535. PubMed 

5. van Rooijen N, Kors N, Kraal G. Characterization of cell populations, reappearing in the mouse spleen after elimination by liposome encapsulated dichloromethylene diphosphonate: reappearance of marginal zone lymphocytes is independent of marginal zone macrophages. Adv Exp Med Biol. 1988;237:889-93. doi: 10.1007/978-1-4684-5535-9_133. PMID: 2978212. PubMed 

6. van Rooijen N, Kors N, Kraal G. Macrophage subset repopulation in the spleen: differential kinetics after liposome-mediated elimination. J Leukoc Biol. 1989 Feb;45(2):97-104. doi: 10.1002/jlb.45.2.97. PMID: 2521666. PubMed 

7. Su D, Van Rooijen N. The role of macrophages in the immunoadjuvant action of liposomes: effects of elimination of splenic macrophages on the immune response against intravenously injected liposome-associated albumin antigen. Immunology. 1989 Mar;66(3):466-70. PMID: 2703258; PMCID: PMC1385238.  PubMed 

8. Thepen T, Van Rooijen N, Kraal G. Alveolar macrophage elimination in vivo is associated with an increase in pulmonary immune response in mice. J Exp Med. 1989 Aug 1;170(2):499-509. doi: 10.1084/jem.170.2.499. PMID: 2526847; PMCID: PMC2189410. PubMed